Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: An effect of pretreatment with rituximab?

Bone Marrow Transplantation

Volumn 42, Issue 7, 2008, Pages 483-487

  Buser, A ^a,b   Stern, M ^a   Arber, C ^a   Medinger, M ^a   Halter, J ^a   Rovo, A ^a   Favre, G ^c   Lohri, A ^c   Tichelli, A ^a   Gratwohl, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Blood Transfusion Centre   (Switzerland)

^c KANTONSSPITAL LIESTAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMSACRINE; ANTHRACYCLINE; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; HYDROXYUREA; IDARUBICIN; IMATINIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON; MELPHALAN; MEPREDNISONE; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HUMORAL IMMUNITY; LARGE CELL CARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MYELOID LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KILLER CELLS, NATURAL; LYMPHOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 54349128837     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.229     Document Type: Article

References (12)

1. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316-2323.
2. Khouri IF. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2006, 390-397.
3. Schmitz N, Dreger P, Glass B, Sureda A. Allogeneic transplantation in lymphoma: Current status. Haematologica 2007; 92: 1533-1548.
4. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446-452.
5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
6. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603-3613.
7. Plosker GL, Figgitt DP. Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-843.
8. Buser AS, Stern M, Bucher C, Arber C, Heim D, Halter J et al. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: A comparison of delayed versus immediate transplantation. Bone Marrow Transplant 2007; 39: 335-340.
9. Arber C, Buser A, Heim D, Weisser M, Tyndall A, Tichelli A et al. Septicpolyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneicHSCT and rituximab pretreatment. Bone Marrow Transplant 2007; 40: 597-598.
10. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
11. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456-473.
12. Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: A single-institution study. Ann Oncol 2007; 18: 364-369.